NetworkNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Lead Candidate Passes FDA-Required Testing, Does Not Cause Cell-Division Damage
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that its lead candidate for treating concussion, ONP-002, does not cause DNA damage and genotoxicity in an animal model. According to the announcement, the company completed a study evaluating ONP-002, a new chemical entity (“NCE”) designed to target the brain through delivery into the nasal cavity and onward to the brain. Testing on cells and animals to ensure a substance does not cause damage affecting cell division is required by the U.S. Food and Drug Administration prior to conducting a clinical…
